Ocugen

Ocugen Advances in Pioneering Gene Therapy for Geographic Atrophy with DSMB Approval to Proceed to Medium Dose in Clinical Trial

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced a significant milestone in its Phase 1/2 …

Ocugen Advances in Pioneering Gene Therapy for Geographic Atrophy with DSMB Approval to Proceed to Medium Dose in Clinical Trial Read More




Annovis Bio

Annovis Bio Makes Strides in Neurodegenerative Disease Treatment: 2023 Q4 Results Below Projections, Progress Seen in Clinical Trials

MALVERN, PA — In a recent financial report for 2023, Annovis Bio, Inc. (NYSE: ANVS) proclaimed progress in the battle against neurodegenerative diseases; however, the path to potential breakthroughs has …

Annovis Bio Makes Strides in Neurodegenerative Disease Treatment: 2023 Q4 Results Below Projections, Progress Seen in Clinical Trials Read More
The Judge Group

The Judge Group Bolsters Leadership Team with Charlton Monsanto as EVP of Integrated Services and Innovation

WAYNE, PA — The Judge Group has announced the appointment of Charlton Monsanto as Executive Vice President of Integrated Services and Innovation. This newly minted role underscores the company’s commitment …

The Judge Group Bolsters Leadership Team with Charlton Monsanto as EVP of Integrated Services and Innovation Read More